Beacon Pointe Advisors LLC Buys 21,690 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Beacon Pointe Advisors LLC grew its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 71.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 52,172 shares of the company's stock after purchasing an additional 21,690 shares during the quarter. Beacon Pointe Advisors LLC's holdings in Hims & Hers Health were worth $1,262,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of HIMS. SlateStone Wealth LLC raised its position in Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company's stock valued at $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. grew its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company's stock worth $480,000 after acquiring an additional 628 shares in the last quarter. Harbour Investments Inc. raised its holdings in shares of Hims & Hers Health by 18.8% in the fourth quarter. Harbour Investments Inc. now owns 5,269 shares of the company's stock valued at $127,000 after purchasing an additional 833 shares during the last quarter. Finally, Stonekeep Investments LLC lifted its position in shares of Hims & Hers Health by 5.5% during the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company's stock valued at $410,000 after purchasing an additional 882 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Leerink Partners upped their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price target for the company from $44.00 to $30.00 in a research report on Tuesday. Piper Sandler lifted their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Bank of America upped their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research note on Tuesday. Finally, Canaccord Genuity Group lifted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health presently has an average rating of "Hold" and an average price target of $36.92.

Hims & Hers Health Stock Up 10.0 %

HIMS opened at $36.39 on Friday. The company has a market capitalization of $8.09 billion, a price-to-earnings ratio of 82.72 and a beta of 1.65. The firm has a 50-day moving average price of $32.19 and a 200-day moving average price of $31.30. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the sale, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. This represents a 56.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Soleil Boughton sold 4,153 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $35.30, for a total transaction of $146,600.90. Following the completion of the transaction, the insider now directly owns 161,497 shares of the company's stock, valued at approximately $5,700,844.10. The trade was a 2.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 666,234 shares of company stock worth $26,387,645. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.